Hypoglycemic Disorder — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypoglycemic disorder. 12 active patents protecting 1 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

1
Approved drugs
12
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypoglycemic Disorder

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Xeris 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypoglycemic disorder. Each bar = one year. Y-axis scaled to peak year (11 patents).

11
36
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Glucagen
GLUCAGON
 Xeris 12 65 — 2036-02-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12370241 Glucagen method of use 75 2036-02-16
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22
10213487 Glucagen method of use 62 2036-02-16
9649364 Glucagen method of use 62 2036-04-22
9649364 Glucagen method of use 62 2036-04-22
9649364 Glucagen method of use 62 2036-04-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10765602 Glucagen formulation 42 2039-09-23
9649364 Glucagen method of use 62 2036-04-22
9649364 Glucagen method of use 62 2036-04-22
9649364 Glucagen method of use 62 2036-04-22
9649364 Glucagen method of use 62 2036-04-22
10213487 Glucagen method of use 62 2036-02-16
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22
11590205 Glucagen method of use 70 2036-04-22

Related